On November 6, President Trump announced that Eli Lilly and Novo Nordisk will offer their GLP-1 weight-loss drugs at a significant discount. As part of the deal, consumers will be able to buy the companies’ products at a significant discount on TrumpRx when it launches. Ozempic and Wegovy will cost $350, and Zepbound and Orforglipron will be $346. If the Food and Drug Administration approves oral GLP-1 drugs manufactured by either company, their cost will be $150 a month through TrumpRx.
The Medicare prices for Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, and Medicare beneficiaries will be liable for a co-pay of $50 per month. Medicare patients with obesity and related comorbidities will be eligible for coverage, although the timeline for coverage expansion is unclear. State Medicaid programs will also have access to these medications at the Medicare prices.
In exchange for the pricing deal, Eli Lilly and Novo Nordisk are expected to receive a three-year tariff exemption.